Gabapentin for overactive bladder and nocturia after anticholinergic failure

International Braz J Urol

Volumn 30, Issue 4, 2004, Pages 275-278

  Kim, Yong T ^a   Kwon, Dong D ^b   Kim, John ^b   Kim, Dae K ^b   Lee, Ji Y ^b   Chancellor, Michael B ^b,c  

^a Chungbuk National University Hospital   (South Korea)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Bladder; Neuromodulation; Nocturia; Prostate; Urination disorders

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETHARGY; MALE; NOCTURIA; OVERACTIVE BLADDER; PATIENT REFERRAL; PATIENT SELECTION; STEADY STATE; SYMPTOMATOLOGY; TREATMENT FAILURE; URINARY FREQUENCY;

EID: 4544268907     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1677-55382004000400002     Document Type: Article

References (7)

1. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998; 280: 1837-42.
2. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280: 1831-36.
3. Gabapentin, Physician Desk Reference, 1999; pp.: 2301-04.
4. Stanfa LC, Singh L, Williams RG, Dickenson AH.: Gabapentin, ineffective in normal rat, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 1997; 8: 587-90.
5. Sasaki K, Smith CP, Chuang YC, Lee JY, Kim JC, Chancellor MB: Oral gabapentin (Neurontin) treatment of refractory genitourinary tract pain. Tech Urology. 2001; 7: 47-9.
6. Yoshimura N, Chancellor MB: Current and future pharmacological therapy of the overactive bladder. J Urol. 2002; 168: 1897-913.
7. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43: 817-24.